melk

MELK-8a hydrochloride is a potent inhibitor of maternal embryonic leucine zipper kinase (MELK, IC50 = 2 nM). 

MELK-IN-1 (MELK inhibitor 17) is a potent inhibitor of maternal embryonic leucine zipper kinase (MELK),(IC50:3nm;Ki:0.39 nM).

HTH-01-091 is a potent and selective maternal embryonic leucine zipper kinase (MELK) inhibitor (IC50: 10.5 nM) that also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2. It can be used to study breast cancer.

JNJ-47117096 hydrochloride is a potent and selective MELK inhibitor with an IC50 of 23 nM and also effectively inhibits Flt3 with an IC50 of 18 nM.

NMS-P715 is a selective and ATP-competitive MPS1 inhibitor(IC50 of 182 nM).

OTSSP167 (OTS167) is an orally available inhibitor of maternal embryonic leucine zipper kinase (MELK) with potential antineoplastic activity.

OTSSP167 hydrochloride is a highly potent inhibitor of MELK(IC50 : 0.41 nM).

MELK-8a (NVS-MELK8a) is a potent and selective inhibitor of maternal embryonic leucine zipper kinase (MELK), with an IC50 of 2 nM and an IC50 of 0.42 μM in cellular assays. MELK is crucial in regulating mitosis in cancer cells.

MRT199665 is an effective and ATP-competitive, selective MARK/SIK/AMPK inhibitor (IC50s of 2/2/3/2 nM, 10/10 nM, and 110/12/43 nM for MARK1/MARK2/MARK3/MARK14, AMPKα1/AMPKα2, and SIK1/SIK2/SIK3, respectively). MRT199665 suppresses the phosphorylation of S

Prexasertib (LY2606368) is a selective checkpoint kinase 1 (CHK1) inhibitor (Ki 0.9 nM, IC50<1 nM). Prexasertib causes double-stranded DNA breaks and replication mutations, leading to apoptosis. Prexasertib has antitumor activity.

Prexasertib dihydrochloride (LY2606368) is an ATP-competitive CHK1 inhibitor (Ki: 0.9 nmol/L). in the cell-free assay, its IC50 values are 8 nM and 9 nM for CHK2 and RSK, respectively.

MELK-8a Dihydrochloride is a useful organic compound for research related to life sciences and the catalog number is T35342.

JNJ-47117096 is a potent and selective MELK inhibitor with an IC50 of 23 nM, and it also exhibits strong activity against Flt3 with an IC50 of 18 nM.

HTH-01-091 TFA, a potent and selective inhibitor of maternal embryonic leucine zipper kinase (MELK), exhibits an IC50 of 10.5 nM. Besides its primary target, it also inhibits PIM1/2/3, RIPK2, DYRK3, smMLCK, and CLK2, positioning it as a promising agent for breast cancer research [1].

Antitumor Agent-116 (Compound 6C) is an anti-tumor agent that exhibits anti-proliferative properties and induces apoptosis. It demonstrates binding affinity for the MELK receptor [1].

JTV-519 hemifumarate,Antiarrhythmic and cardioprotective properties. is a Ca2+-dependent blocker of sarcoplasmic reticulum Ca2+-stimulated ATPase (SERCA) and a partial agonist of ryanodine receptors in striated muscle.

Onvansertib (NMS-1286937) is a PLK1 inhibitor (IC50=2 nM) with high selectivity and oral activity. Onvansertib has antitumor activity and inhibits tumor growth.

JW-7-25-1 is a potent multi-target inhibitor, acting on MELK, PIK3CA, mTOR, GSK3A and CDK7.

FMF-06-098-1 is a multitargeted depressant that promotes the degradation of various kinases including AAK1, ABL2, AURKA, AURKB, BUB1B, CDC7, CDK1, CDK12, CDK13, CDK2, CDK4, CDK6, CDK7, CDK9, CHEK1, CSNK1D, EPHA1, PAK, FGFR1, GAK, IRAK4, ITK, LIMK2, MAP4K2, MAP4K3, MAPK6, MAPK7, MARK4, MELK, PKN3, PLK4, PRKAA1, PTK2, PTK6, RPS6KA4, SGK2, STK35, TNK2, UHMK1, ULK1, and WEE1 [1].